HC Wainwright Reiterates "Buy" Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)

HC Wainwright reaffirmed their buy rating on shares of Corvus Pharmaceuticals (NASDAQ:CRVS - Free Report) in a research report sent to investors on Tuesday,Benzinga reports. HC Wainwright currently has a $11.00 price target on the stock.

A number of other equities analysts have also weighed in on CRVS. StockNews.com lowered shares of Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, October 31st. Mizuho upgraded shares of Corvus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, October 22nd. Oppenheimer boosted their target price on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an "outperform" rating in a report on Wednesday, November 13th. Finally, LADENBURG THALM/SH SH boosted their price objective on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a "buy" rating in a research note on Monday, September 16th. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Corvus Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $12.38.

Corvus Pharmaceuticals Price Performance

Shares of NASDAQ:CRVS traded down $0.10 during midday trading on Tuesday, hitting $5.10. 629,439 shares of the company's stock were exchanged, compared to its average volume of 732,794. The company has a market cap of $327.73 million, a PE ratio of -5.48 and a beta of 1.05. Corvus Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $10.00. The stock has a 50 day moving average price of $7.20 and a 200-day moving average price of $5.52.

Institutional Trading of Corvus Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Samlyn Capital LLC lifted its position in shares of Corvus Pharmaceuticals by 160.7% in the 2nd quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company's stock worth $11,144,000 after purchasing an additional 3,774,658 shares during the period. Point72 Asset Management L.P. purchased a new position in shares of Corvus Pharmaceuticals during the 2nd quarter valued at $10,855,000. Geode Capital Management LLC grew its stake in Corvus Pharmaceuticals by 22.4% during the third quarter. Geode Capital Management LLC now owns 563,009 shares of the company's stock valued at $2,974,000 after acquiring an additional 102,869 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in Corvus Pharmaceuticals by 64.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company's stock valued at $724,000 after purchasing an additional 53,809 shares in the last quarter. Finally, State Street Corp boosted its stake in Corvus Pharmaceuticals by 48.2% during the third quarter. State Street Corp now owns 178,246 shares of the company's stock worth $941,000 after buying an additional 57,943 shares during the period. Hedge funds and other institutional investors own 46.64% of the company's stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.